Toezicht op minimum maaswijdte

De vangst en sterfte van vis wordt hoofdzakelijk bepaald door de maaswijdte (of maasopening) in de kuil van het gebruikte visnet. Meting van maaswijdte is niet eenvoudig en de huidige regelgeving is aan kritiek onderhevig. Dit heeft geleid tot de ontwikkeling van een nieuw meetprotocol en meetinstrument. De visserij op tong met 80 mm en een minimummaat van 24 cm is gevoelig voor een juiste vaststelling van de maaswijdte van de kuil. Dit rapport behandelt statistische en juridische aspecten van de huidige regelgeving en de eventuele invoering van de nieuwe OMEGA-maaswijdtemeter

Proeven aan de FishWing

In oktober 2013 is een proef uitgevoerd aan boord van de LT34 “Jupiter” met de zgn. “FishWing”, een boomkor met een speciale vleugel in vergelijking met een conventioneel 5 m boomkortuig met wekkers en kietelaars . Het vistuig was ontworpen om door verandering van de waterstroming erdoorheen een vermindering van ongewenste bijvangsten te krijgen. Tijdens de ontwerpfase zijn modelproeven uitge-voerd in een sleeptank in Duitsland, die aangaven, dat er onder de vleugel een drukvermindering op-treedt, waardoor platvis zonder wekkers zou kunnen worden gestimuleerd de bodem te verlaten. De totale vangsten (zowel in aantallen als kilo’s per uur) waren voor de FishWing zowel qua aanlanding (ca. 30% minder in kg per uur) als vis discards (ca. 47% minder in kg per uur) en benthos (ca. 49% minder in kg per uur) duidelijk lager dan die van de conventionele boomkor. Door de grote afmetingen van de FishWing was deze moeilijk hanteerbaar op dit kleine schip

Study protocol for THINK : a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types

Introduction: NKR-2 are autologous T cells genetically modified to express a chimeric antigen receptor (CAR) comprising a fusion of the natural killer group 2D (NKG2D) receptor with the CD3 zeta signalling domain, which associates with the adaptor molecule DNAX-activating protein of 10 kDa (DAP10) to provide co-stimulatory signal upon ligand binding. NKG2D binds eight different ligands expressed on the cell surface of many tumour cells and which are normally absent on non-neoplastic cells. In preclinical studies, NKR-2 demonstrated long-term antitumour activity towards a breadth of tumour indications, with maximum efficacy observed after multiple NKR-2 administrations. Importantly, NKR-2 targeted tumour cells and tumour neovasculature and the local tumour immunosuppressive microenvironment and this mechanism of action of NKR-2 was established in the absence of preconditioning. Methods and analysis: This open-label phase I study will assess the safety and clinical activity of NKR-2 treatment administered three times, with a 2-week interval between each administration in different tumour types. The study will contain two consecutive segments: a dose escalation phase followed by an expansion phase. The dose escalation study involves two arms, one in solid tumours (five specific indications) and one in haematological tumours (two specific indications) and will include three dose levels in each arm: 3x10(8), 1x10(9) and 3x10(9) NKR-2 per injection. On the identification of the recommended dose in the first segment, based on dose-limiting toxicity occurrences, the study will expand to seven different cohorts examining the seven different tumour types separately. Clinical responses will be determined according to standard Response Evaluation Criteria In Solid Tumors (RECIST) criteria for solid tumours or international working group response criteria in haematological tumours. Ethics approval and dissemination: Ethical approval has been obtained at all sites. Written informed consent will be taken from all participants. The results of this study will be disseminated through presentation at international scientific conferences and reported in peer-reviewed scientific journals

Netinnovatie Kottervisserij

Als reactie op de aanlandplicht heeft de kottersector via de Coöperatieve Visserij Organisatie (CVO) het initiatief opgepakt om de selectiviteit van de vistuigen te verhogen om zo weinig mogelijk discards te vangen en aan te landen. Na een ontwerpfase met modelonderzoek in de flume tank van SINTEF te Hirtshals, Denemarken, en met ervaringen uit eerdere projecten werden op verscheidene schepen netinnovaties uitgeprobeerd. Er werd onderzoek gedaan op een schip met boomkor, verschillende schepen vissend met pulsvistuigen en op twinriggers. Hierbij werd aanvankelijk gewerkt op ‘trial-and error’ basis met in sommige gevallen zelfmonitoring. Vervolgens werden enkele uitgebreide vangst- en bijvangstvergelijkingen gedaan met medewerkers van IMARES aan boord

Pembrolizumab for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of treatment options from the phase III KEYNOTE-040 trial

n/

A naming convention for the Piano Key Weirs geometrical parameters

Flood management is more than ever an issue for dam designers and engineering consulting firms in charge of rehabilitation works. Piano Key Weirs are a new cost-effective type of spillway designed to improve dams discharge capacity. These structures are particularly attractive: they can easily be built on existing structures and enable very high discharge capacities. Therefore, Piano Key Weirs are nowadays studied worldwide. Piano Key Weir description involves a lot of geometrical parameters (more than 30), which designations are not already universally defined. A naming convention is required to enhance exchanges and cooperation between the numerous developers. A naming convention has been developed at EDF – Hydro Engineering Center in cooperation with the Laboratory of Hydraulic Constructions (LCH), Ecole Polytechnique Fédérale de Lausanne and the Laboratory of Hydrology, Applied Hydrodynamics and Hydraulic Constructions (HACH), University of Liege. This paper describes the proposed naming convention and gives definitions and notations of the various geometrical parameters. This work represents a first attempt which should be updated with the contribution of stakeholders involved in this topic

Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials

In this study we examined the outcome of metastatic renal cell cancer patients with everolimus treatment-related hyperglycemia and hypercholesterolemia. All patients were treated in 2 large, international prospective trials, RECORD-1 (REnal Cell cancer treatment with Oral RAD001 given Daily) and REACT (RAD001 Expanded Access Clinical Trial in RCC). Patients who experienced these events might have experienced an improved response to everolimus. Background Hyperglycemia and hypercholesterolemia are class effects of mammalian target of rapamycin inhibitors. The purpose of this study was to characterize safety and efficacy of patients with metastatic renal cell carcinoma (mRCC) treated with everolimus in RECORD-1 (REnal Cell cancer treatment with Oral RAD001 given Daily) and REACT (RAD001 Expanded Access Clinical Trial in RCC) who developed these events. Patients and Methods Adults with vascular endothelial growth factor–refractory mRCC received everolimus 10 mg/d in the randomized RECORD-1 (n = 277) and open-label REACT (n = 1367) studies. Outcomes included safety, treatment duration, overall response, and progression-free survival for patients who developed hypercholesterolemia or hyperglycemia. Results In RECORD-1, 12% (33 of 277) and 20% (55 of 277) of patients developed any grade hyperglycemia or hypercholesterolemia, respectively, with only 6% (78 of 1367) and 1% (14 of 1367) of the same events, respectively, in REACT. Median everolimus treatment duration was similar for patients with hyperglycemia or hypercholesterolemia (RECORD-1, 6.2 and 6.2 months, respectively; REACT, 4.4 and 4.5 months, respectively), but longer than the overall populations (RECORD-1, 4.6 months; REACT, 3.2 months). In RECORD-1/REACT, 82%/68% of patients with hyperglycemia and 75%/71% of patients with hypercholesterolemia achieved partial response or stable disease. The incidence of clinically notable Grade 3 or 4 adverse events, other than anemia and lymphopenia, appeared to be similar across trials and subgroups. Although there was a trend for improved progression-free survival with development of hyperglycemia or hypercholesterolemia, the association was not statistically significant. Conclusion Hyperglycemia and hypercholesterolemia were observed in low numbers of patients, and although these events might be associated with improved response to everolimus, the differences were not significant. These findings should be validated with prospective biomarker studies

keynote 412 phase iii study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma hnscc

n/